alefacept + tacrolimus

**Alefacept + tacrolimus** is a combination of two immunosuppressive agents used experimentally or in clinical trials, primarily for managing immune-mediated conditions such as organ transplant rejection and graft-versus-host disease (GvHD). Alefacept is a recombinant human LFA3/IgG1 fusion protein that binds to CD2 on T cells, blocking the LFA-3/CD2 interaction and selectively depleting memory T cells via apoptosis. This reduces T cell activation and proliferation[2][4]. Tacrolimus is a macrolide small molecule calcineurin inhibitor that suppresses T-lymphocyte activity by inhibiting IL-2 transcription, thus preventing T cell-mediated immune responses[3]. Together, these agents target complementary pathways of T cell activation and survival. The combination has been studied for acute steroid-resistant or dependent GvHD and in de novo kidney transplantation, with efficacy in reducing memory T cell counts but uncertain impact on clinical endpoints[1][5].

Brand names

AstagrafEnvarsusModigrafTacforius

Other names

alefacept + tacrolimusLFA3-IgG1 fusion protein + FK-506